Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells

20 Aug 2025

Abstract excerpt

ABSTRACT: The consequences of activated innate immune signaling in acute myeloid leukemia (AML) is not well understood. Using ligands directed at the toll-like family receptors (TLR) in models of high-risk AML, we uncover that TLR2 ligands exert unique antileukemic effects that are distinct from other TLRs. Although TLR2 signaling broadly induces inflammatory gene expression in AML cells, at the single-cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Immune cells in cancer
Share to Immune Response and Inflammation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40833891
DOI: 10.1182/bloodadvances.2025017018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cellsPMID 40833891Read ↗

Systemic TLR2 agonist exposure regulates hematopoietic stem cells via cell-autonomous and cell-non-autonomous mechanisms.Semantic proximity Read ↗

Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Semantic proximity Read ↗

IL2RA Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid LeukemiaSemantic proximity Read ↗

The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fateSemantic proximity Read ↗

IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cellsSemantic proximity Read ↗

Targeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and RelapseSemantic proximity Read ↗

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AMLSemantic proximity Read ↗

Human ILC1s target leukemia stem cells and control development of AMLSemantic proximity Read ↗

Toll-like receptor alterations in myelodysplastic syndrome.Semantic proximity Read ↗

SIRPα+ PD-L1+ bone marrow macrophages aid AML growth by modulating T cell functionSemantic proximity Read ↗

The Caspase-1-EGR4 axis drives acute myeloid leukemia progression by orchestrating macrophage repolarizationSemantic proximity Read ↗

Clinical Implication of Toll-Like Receptors (TLR2 and TLR4) in Acute Myeloid Leukemia Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.